Condition
Recurrent Merkel Cell Carcinoma
Total Trials
5
Recruiting
0
Active
1
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
66.7%
-19.8% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results67% success
Data Visualizations
Phase Distribution
5Total
P 1 (3)
P 2 (2)
Trial Status
Completed2
Withdrawn1
Terminated1
Active Not Recruiting1
Trial Success Rate
66.7%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT03074513Phase 2Active Not Recruiting
Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors
NCT02267603Phase 2CompletedPrimary
Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer
NCT02831179Phase 1Withdrawn
Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor
NCT01758458Phase 1TerminatedPrimary
Viral Oncoprotein Targeted Autologous T Cell Therapy for Merkel Cell Carcinoma
NCT01204476Phase 1Completed
Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma
Showing all 5 trials